|
Mar 5
|
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
|
|
Feb 20
|
Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests
|
|
Feb 20
|
RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure.
|
|
Feb 20
|
UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials
|
|
Feb 20
|
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
|
|
Feb 20
|
FDA puts hold on Rapt trials of drug for eczema, asthma
|
|
Jan 2
|
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 27
|
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
|
|
Aug 8
|
This RAPT Therapeutics Insider Increased Their Holding By 22% Last Year
|